AKT1 - A New Marker for Tamoxifen Resistance in ER-Dependent Breast Cancer
Abstract
While the significance of the serine/threonine protein kinase AKT expression and/or activity in human breast cancer has become increasingly evident, consistent alterations of a specific isoform have not been well documented. A specific isoform of AKT may be preferentially activated or activated proteins may have different substrate preferences, providing a therapeutic opportunity to target a particular isoform. The primary endpoint is to compare responsiveness to tamoxifen in ER-alpha-positive, ErbB2 low tumors with high AKT1 activity versus no AKT1 activity. 7 tumors each of 1) ER-alpha-positive, ErbB2 high; 2) ER-alpha-positive, ERbB2 low; 3) ER-alpha-positive, no ErbB2; 4) ER-negative, ErbB2 high; 5) ER- negative, ErbB2 low; and 6) ER-negative, no ErbB2 will be tested for AKT (AKT1, AKT2, AKT3), ErbB (EGFR, ErbB2, ErbB3, and ErbB4) and ER-a expression and activity. We have received 26 tumors and their surrounding normal tissue. Paraffin sections were prepared from most of these tissues and the sections were immunostained with total anti-Akt, phosphospecific anti-Akt, anti-progesterone receptor, total and phosphospecific antibody against ErbB2. We are in the process of scoring of these paraffin sections. In addition, we prepared cell lysates and RNA from the tumors and normal tissues for further analyses.
Document Details
- Document Type
- Technical Report
- Publication Date
- Sep 01, 2004
- Accession Number
- ADA432994
Entities
People
- Adriana Stoica
Organizations
- Georgetown University